Lucence
Precision oncology company dedicated to creating state-of-the-art, highly sensitive liquid biopsy tests for early disease detection and personalized treatment selection.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
$20.0m | Series A | ||
| Total Funding | 000k | ||
Related Content
Lucence is a pioneering company in the field of precision cancer care, specializing in ultrasensitive and non-invasive liquid biopsy tests. These tests are designed to detect and profile cancer using a single blood draw, making early detection more accessible and affordable. Lucence serves a diverse range of clients, including physicians and patients, who require accurate and actionable insights to guide their medical care. Operating in the healthcare and biotechnology market, Lucence leverages its proprietary technologies to capture both sequence and cell information, providing comprehensive cancer profiling. The company's business model revolves around offering these advanced diagnostic tests, generating revenue through the sale of their liquid biopsy solutions. By focusing on early cancer detection, Lucence aims to transform cancer care and improve patient outcomes.
Keywords: liquid biopsy, cancer detection, precision care, non-invasive, blood test, biomarkers, early detection, healthcare, biotechnology, diagnostics.